

Daniela Marotto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8739058/daniela-marotto-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15
papers

504
citations

10
h-index

16
g-index

16
ext. papers

693
ext. citations

6.5
avg, IF

4.54
L-index

#	Paper	IF	Citations
15	Rheumatoid Arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. <i>Acta Biomedica</i> , 2021 , 92, e2021238	3.2	0
14	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. <i>Journal of Autoimmunity</i> , 2021 , 116, 102545	15.5	18
13	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 695	2.2	
12	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. <i>Autoimmunity Reviews</i> , 2020 , 19, 102574	13.6	29
11	Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. <i>Radiologia Medica</i> , 2020 , 125, 636-646	6.5	88
10	What is the role of rheumatologists in the era of COVID-19?. <i>Autoimmunity Reviews</i> , 2020 , 19, 102539	13.6	21
9	Extra-intestinal manifestations of inflammatory bowel diseases. <i>Pharmacological Research</i> , 2020 , 161, 105206	10.2	6
8	The role of a chest computed tomography severity score in coronavirus disease 2019 pneumonia. <i>Medicine (United States)</i> , 2020 , 99, e22433	1.8	12
7	Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 645-660	8.1	62
6	Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 123, 53-59	2.2	6
5	COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 337-342	2.2	218
4	Cannabinoids in the treatment of rheumatic diseases: Pros and cons. <i>Autoimmunity Reviews</i> , 2019 , 18, 102409	13.6	18
3	Medical cannabis and cannabinoids in rheumatology: where are we now?. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 1019-1032	5.1	11
2	Fibromyalgia and the concept of resilience. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 116, 105-113	2.2	10
1	A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout. <i>Rheumatology and Therapy</i> , 2018 , 5, 303-310	4.4	4